Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP2 | P08253 | 13/20 | 0.69 |
| ▸ | MMP3 | P08254 | 11/20 | 0.69 |
| ▸ | MMP13 | P45452 | 11/20 | 0.69 |
| ▸ | MMP9 | P14780 | 11/20 | 0.69 |
| ▸ | MMP1 | P03956 | 10/20 | 0.69 |
| ▸ | MMP7 | P09237 | 10/20 | 0.69 |
| ▸ | ADAMTS4 | O75173 | 6/20 | 0.69 |
| ▸ | MMP8 | P22894 | 1/20 | 0.56 |
| ▸ | MMP14 | P50281 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14419201 | 0.92 | MMP9 (0.56) | MMP2MMP3MMP13MMP9MMP1 | |
| SCHEMBL8283343 | 0.90 | ADAMTS4 (0.67) | MMP2MMP3MMP13MMP9MMP1 | |
| SCHEMBL1655654 | 0.90 | ADAMTS4 (0.67) | MMP2MMP3MMP13MMP9MMP1 | |
| SCHEMBL3608273 | 0.89 | MMP2 (0.68) | MMP2MMP3MMP13MMP9MMP1 | |
| SCHEMBL7867746 | 0.89 | MMP2 (0.68) | MMP2MMP3MMP13MMP9MMP1 | |
| SCHEMBL3608270 | 0.89 | MMP2 (0.68) | MMP2MMP3MMP13MMP9MMP1 | |
| SCHEMBL7763738 | 0.89 | MMP2 (0.68) | MMP2MMP3MMP13MMP9MMP1 | |
| SCHEMBL7867268 | 0.88 | MMP2 (0.71) | MMP2MMP3MMP13MMP9MMP1 | |
| SCHEMBL1656422 | 0.87 | ADAMTS4 (0.77) | MMP2MMP13ADAMTS4MMP14 | |
| SCHEMBL12808878 | 0.87 | MMP2 (0.76) | MMP2MMP3MMP13MMP9MMP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110124653-A1 | ARYL-SULPHONAMIDIC DIMERS AS METALLOPROTEASES INHIBITORS | BRACCO IMAGING S.P.A. (IT) | 2011-05-26 | — | — | US | disclosed |
| US-20110124653-A1 | ARYL-SULPHONAMIDIC DIMERS AS METALLOPROTEASES INHIBITORS | BRACCO IMAGING S.P.A. (IT) | 2011-05-26 | — | — | US | disclosed |
| EP-2149568-A1 | ARYL-SULPHONAMIDIC DIMERS AS METALLOPROTEASES INHIBITORS | Bracco Imaging S.p.A (IT) | 2010-02-03 | — | — | EP | disclosed |
| WO-2010010080-A1 | ARYL-SULPHONAMIDIC DIMERS AS METALLOPROTEASES INHIBITORS | BRACCO IMAGING SPA (IT) | 2010-01-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110124653-A1 | ARYL-SULPHONAMIDIC DIMERS AS METALLOPROTEASES INHIBITORS | MMP9, MMP1, MMP2 | MMP2 3/4885MMP3 5/4885MMP13 19/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.